Autolus Therapeutics PLC

Autolus Therapeutics plc announced a significant increase in its 2026 revenue guidance for AUCATZYL and secured a substantial credit facility, extending its cash runway into Q2 2028.

Autolus Therapeutics plc has entered into a $250 million senior secured notes facility with Perceptive Credit Holdings V, LP, alongside the issuance of warrants, to fund its operations and development.

Autolus Therapeutics plc has published its UK Annual Report and Accounts for the year ended December 31, 2025, and has issued a notice for its upcoming Annual General Meeting.

Autolus Therapeutics plc announced first quarter 2026 financial results, reporting a significant increase in AUCATZYL net product revenue to $26.2 million and achieving positive gross margin for its acute lymphoblastic leukemia business.

Autolus Therapeutics plc is implementing a workforce reduction of approximately 13% to improve operational efficiency and reduce operating expenses, while reiterating its 2026 revenue guidance.

Autolus Therapeutics has dismissed Ernst & Young LLP (UK) and appointed Ernst & Young LLP (US) as its new independent auditor.

Autolus Therapeutics plc announced its first-quarter 2026 financial results, highlighting significant growth in product revenue from AUCATZYL and providing updates on its clinical pipeline.

Autolus Therapeutics reports significant product revenue from AUCATZYL in Q3 2025, alongside ongoing clinical advancements and strategic market expansion efforts.

Autolus Therapeutics reports initial US product revenue for AUCATZYL but faces significant commercialization hurdles in Europe and increased net losses.

Autolus Therapeutics announces its Q1 2025 financial results, marking the first commercial sales of AUCATZYL and providing updates on its clinical programs.

Autolus Therapeutics announced FDA approval for AUCATZYL and provided a financial update for the third quarter of 2024, highlighting increased operating expenses and a net loss.

Autolus Therapeutics reports a net loss of $58.3 million for the second quarter of 2024, alongside significant advancements in their clinical programs and a strengthened financial position.

Autolus Therapeutics reports its first commercial sales of AUCATZYL in the US, expands its CAR T-cell therapy pipeline for oncology and autoimmune diseases, and continues to incur significant losses.

Autolus Therapeutics announces FDA approval for AUCATZYL and reports financial results for the year ended December 31, 2024, highlighting commercial launch preparations and pipeline development.

Autolus Therapeutics submits a BLA to the FDA for obe-cel in r/r adult B-ALL and reports full year 2023 financial results.

Autolus Therapeutics plc reports a Form 4 filing detailing Director William D. Young's acquisition of restricted stock units and share options.

Ryan Richardson, a Director at Autolus Therapeutics plc, has acquired restricted stock units and share options.

Autolus Therapeutics Director Elisabeth Leiderman acquired restricted stock units and share options, signaling confidence in the company's future.

Autolus Therapeutics plc reports a Form 4 filing detailing Robert Iannone's acquisition of restricted stock units and share options.

Autolus Therapeutics Director Cynthia M. Butitta acquired restricted stock units and share options, increasing her beneficial ownership.

Autolus Therapeutics plc reports a Form 4 filing detailing share transactions by Director Linda Bain, including the acquisition of restricted stock units and share options.

Autolus Therapeutics has filed a registration statement for the resale of up to 54,584,250 American Depositary Shares (ADSs) by existing securityholders, including Blackstone and BioNTech.

Investment firm MAK Capital and Michael A. Kaufman have reported a 12.6% beneficial ownership stake in Autolus Therapeutics plc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,800,000 American Depositary Shares of Autolus Therapeutics plc, representing 5.94% of the class.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman jointly reported an 11.3% beneficial ownership stake in Autolus Therapeutics PLC.

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman collectively reported a 10.1% beneficial ownership in Autolus Therapeutics plc.

Armistice Capital, LLC and Steven Boyd have reported a passive beneficial ownership of 5.86% in Autolus Therapeutics plc, holding 15.6 million American Depositary Shares.

Deep Track Capital and affiliates have reduced their beneficial ownership in Autolus Therapeutics plc to 0.97%, falling below the 5% threshold.